December 13, 2020 - FDA, United States

COVID-19: FDA and Compliance Issues with Testing, Vaccines, and Therapies

We are finally starting to see into the future, understanding the ways COVID-19 is changing the future of FDA regulatory process and advancing innovation to meet the needs of today’s patients.  Thanks to all the attendees for such amazing questions and contributions!” commented MoFo partner and head of our FDA Regulatory + Life Sciences Compliance practice Bethany Hills at the end of our session 4 of the GSAS Harvard Biotech Club and Morrison & Foerster course on Legal Topics for Scientists, Entrepreneurs, and Start UpsCOVID-19: FDA and Compliance Issues with Testing, Vaccines, and Therapies.

Biotech and Pharma IP Litigation will be our focus for this week with IP Litigation partner Matthew Chivvis leading the session 5 on Considerations for ANDA and BPCIA Litigation.